Lb Pharmaceuticals (LBRX) Operating Expenses (2024 - 2026)

Lb Pharmaceuticals' Operating Expenses history runs 3 years deep, the most recent figure standing at $22.1 million for Q1 2026.

• In Q1 2026, Operating Expenses rose 243.82% year-over-year to $22.1 million; the TTM figure through Mar 2026 stood at $47.6 million (changed N/A YoY), while the FY2025 annual figure was $30.4 million, down 53.1% from the prior year.
• Operating Expenses was $22.1 million for Q1 2026 at Lb Pharmaceuticals, up from $13.9 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $22.1 million in Q1 2026 to a low of $5.2 million in Q3 2025.
• Historically, Operating Expenses has averaged $11.5 million across 3 years, with a median of $10.1 million in 2025.
• The sharpest annual moves came in 2025 and 2026: Operating Expenses plunged 67.38% in 2025, then jumped 243.82% in 2026.
• A 3-year view of Operating Expenses shows it stood at $5.5 million in 2024, then jumped by 150.41% to $13.9 million in 2025, then jumped by 59.37% to $22.1 million in 2026.
• The last three Operating Expenses figures came in at $22.1 million (Q1 2026), $13.9 million (Q4 2025), and $5.2 million (Q3 2025), per Business Quant data.